Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirum Pharmaceuticals reports robust Q4 performance and growth strategies

Mirum Pharmaceuticals showcased strong financial performance and strategic growth initiatives in their Q4 2022 earnings call, driven by significant sales growth and positive study outcomes.
While the company faces challenges in maintaining market position and regulatory milestones, opportunities lie in upcoming milestones, product expansion, and market penetration strategies.
Overall, Mirum Pharmaceuticals' performance reflects a promising outlook for continued growth and innovation in the pharmaceutical sector, supported by a solid financial foundation and product pipeline.

Mirum Pharmaceuticals reports strong Q1 revenue and strategic growth plans

Mirum Pharmaceuticals' Q1 2023 earnings call showcased strong revenue performance, strategic initiatives, and promising pipeline milestones. The company's focus on LIVMARLI and expansion efforts position it well for future growth, despite facing regulatory and commercial challenges.

Mirum Pharmaceuticals reports robust Q2 performance and eyes strategic growth

Mirum Pharmaceuticals showcased strong financial performance, strategic progress, and a focus on innovation during the Q2 2023 earnings call.
The company's emphasis on pediatric hepatology, upcoming acquisitions, and commitment to bringing important medicines to patients globally position it for future success.
While facing challenges such as regulatory strategies and integration post-acquisition, Mirum has opportunities to drive growth through product expansion and market leadership.

Mirum Pharmaceuticals reports strong Q3 revenue and strategic acquisitions

Mirum Pharmaceuticals demonstrated solid performance in Q3 2023 with strong revenue and strategic acquisitions.
While facing challenges such as net losses and high operating expenses, the company maintains a strong financial position.
Opportunities lie in upcoming milestones, product commercialization, and financial optimization under new leadership.
Overall, Mirum Pharmaceuticals shows promise for growth and innovation in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q4 earnings and growth opportunities

Mirum Pharmaceuticals delivered strong financial results in Q4 2023, with significant revenue growth and net product sales.
Despite operating expenses and a net loss, the company remains well-funded and poised for growth in 2024.
Key milestones and progress in pipeline development highlight Mirum's commitment to innovation and market expansion.
Balancing financial performance with pipeline advancement and regulatory milestones will be crucial for Mirum's sustained success in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q1 sales growth and pipeline advancements

Mirum Pharmaceuticals demonstrated strong sales growth and financial stability in Q1 2024, driven by the success of LIVMARLI and advancements in product pipeline.
While facing challenges in managing expenses and navigating a competitive market, Mirum's focus on rare liver disease treatments presents significant opportunities for growth.
The company's commitment to innovation, gratitude for stakeholders, and strategic plans for NDA submissions underscore a promising outlook for future success.
Investors should monitor Mirum's progress in commercializing key products and expanding its market reach to capitalize on the growth potential in rare disease treatments.

Mirum Pharmaceuticals excels in Q2, eyes global expansion and innovation

Mirum Pharmaceuticals demonstrated impressive growth and achieved key milestones in Q2 2024, positioning the company for future success.
While facing challenges such as net losses and market competition, Mirum's strengths in product innovation and market expansion offer opportunities for sustained growth.
By focusing on cost management, regulatory compliance, and strategic partnerships, Mirum can navigate challenges and capitalize on opportunities to drive long-term value for stakeholders.

Mirum Pharmaceuticals excels in Q3, raises revenue guidance and expands pipeline

Mirum Pharmaceuticals delivered exceptional results in Q3 2024, showcasing strong financial performance, robust commercial programs, and promising pipeline advancements. With increased revenue guidance, breakthrough designations, and positive cash flow, the company is well-positioned for continued success. Challenges lie in maintaining growth momentum amidst competition and regulatory complexities, but opportunities for expansion and innovation abound.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Corporate Update

Mirum Pharmaceuticals Provides Corporate Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

Mirum Pharmaceuticals (MIRM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Mirum Pharmaceuticals (MIRM) in Focus: Stock Moves 5.9% Higher

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement

Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Virtual Investor Day 2020

Mirum Pharmaceuticals Announces Virtual Investor Day 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #AASLD--Mirum Data Presented at AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with ALGS Treated with Maralixibat

Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents New Data From its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia

Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the AASLD Annual Meeting

Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

MoA reduces bile acid systemic levels. Potential utility across wide range of rare liver diseases.

Mirum: Upcoming Catalyst In Rare Liver Disease, Strong Pipeline And Data

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020

FOSTER CITY, Calif., Oct. 15, 2020 /PRNewswire/ -- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it has partnered with EVERSANA™, a leading...

Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Investor Conferences in September

Mirum Pharmaceuticals to Present at Investor Conferences in September

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum initiates rolling NDA submission for maralixibat for the treatment of cholestatic pruritus in patients with ALGS & launches EAP

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients with PFIC2 at Digital International Liver Congress

Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

Mirum Pharmaceuticals: Undervalued Rare Disease Player With Clear Path To Market

It appears the FDA is willing to work with Mirium to get maralixibat approved as quickly as possible.

Here's Why Mirum Pharmaceuticals Rocketed 240% in December

Mirium Pharmaceuticals Inc. (NASDAQ:MIRM) shares continue to soar, having nearly tripled since mid-December after it had a successful pre-New Drug Application meeting with the Food and Drug Administration regarding Maralixibat, the company’s treatment for pruritus, which is associated with Alagille syndrome.

Despite Recent Gains, Mirium Shares Still Rated a Buy

This newly public drug developer tripled its stock price in November following positive FDA news.

Here's Why Mirum Pharmaceuticals' Stock Jumped in December

The company's clinical trial is taking an important step forward.

Why Mirum Pharmaceuticals Stock Skyrocketed 44% Today

Mirum Pharmaceuticals And Maralixibat In Alagille Syndrome

News for Mirum Pharmaceuticals Inc Stock (MIRM)